UroGen (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma (URGN) reported Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier, driven by ZUSDURI commercial launch. ZUSDURI revenue was $50.4 million, up 73% vs Q1 2026. JELMYTO revenue was $22.0 million. Net loss was $14.4 million. Cash was $108 million. 2026 operating expense guidance is $260-$270 million; JELMYTO revenue guidance is $97-$101 million.
How this was made
The 30-second read
Why it matters
Key decision inputs include updated revenue mix, activated accounts and prescriber metrics, full-year operating expense guidance, JELMYTO revenue guidance, cash balance, and new IP and settlement details that affect competitive dynamics.
Market read
The call supplies fresh quantitative guidance and commercial KPIs that can drive near-term repricing of URGN’s growth and cost trajectory.
What to watch
The transcript highlights patent and reimbursement tailwinds, but traders should also weigh execution risk around Phase III timing for UGN-103 and the commercial impact of competitor trial enrollment taking potential JELMYTO patients.
Background
UroGen’s Q2 2026 call centers on commercialization of ZUSDURI and JELMYTO, plus ongoing development of UGN-103 and UGN-501.
Ticker impact
UroGen reported Q2 2026 revenue of $72.5M, guided 2026 operating expenses to $260M-$270M, and updated ZUSDURI and JELMYTO performance.
Near-term bias modestly positive if investors focus on ZUSDURI growth and cash runway, but volatility risk remains from JELMYTO softness and enrollment seasonality commentary.
Multiple new quantitative datapoints (revenue mix, activated accounts, prescriber growth, net loss, cash balance, and full-year guidance) can re-anchor valuation and expectations, though the transcript also flags potential quarter-to-quarter variability and JELMYTO decline.
Market effects
Reinforces the commercial viability of nonsurgical bladder cancer options and the importance of community practice adoption and reimbursement access.
No clear regional-specific impact beyond US reimbursement and urology practice dynamics.
Limited direct global read-through; primarily US commercialization and FDA-regulated development timelines.
Counterpoint
ZUSDURI growth may be partially offset by JELMYTO stagnation and potential enrollment seasonality, so the net earnings power story could be less durable than the headline revenue growth suggests.
Key entities
- companyUroGen Pharma Ltd.
Reported Q2 2026 financials and provided 2026 guidance, commercialization metrics, and development/regulatory updates on ZUSDURI, JELMYTO, UGN-103, and UGN-501.
- productZUSDURI
Commercial launch driver; Q2 2026 revenue $50.4M, up 73% vs prior quarter, with community practice adoption rising.
- productJELMYTO
Reported Q2 2026 revenue $22M, up 1% QoQ but down vs Q2 2025, with full-year revenue guidance $97M-$101M.
- counterpartyTeva
Settlement with UroGen over JELMYTO patent litigation, granting a non-exclusive generic license starting Sept. 15, 2030.
- regulatorFDA
Cleared UGN-501 IND, with Phase I expected to begin in Q4 2026.
